Managing Medullary Thyroid Cancer with Cushing's Syndrome Due to Ectopic ACTH or CRH

This protocol covers metastatic medullary thyroid carcinoma (MTC) complicated by Cushing's syndrome caused by ectopic secretion of ACTH or CRH from the tumour. Despite a poor prognosis, patients in this setting warrant active treatment to control the cortisol-driven manifestations.

Clinical Scenario

Cushing's syndrome — ectopic ACTH / CRH

Ectopic production of CRH or ACTH by metastatic MTC leads to Cushing's syndrome, often leaving patients markedly debilitated. This comorbidity is the defining feature of the scenario and directly drives the therapeutic priority: control and normalisation of elevated serum cortisol levels.

Treatment Approach (partial overview)

Management targets cortisol excess through medical therapy — the strategy focuses on agents that suppress or block cortisol production or action.

The complete protocol specifies the agents involved, how they are selected, and the clinical targets used to gauge response. Access the full regimen below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1089/thy.2014.0335

Patients with metastatic MTC and Cushing's syndrome due to ectopic production of ACTH or CRH are often markedly debilitated and should be treated despite their poor prognosis.

The most common ectopic hormones, CRH or ACTH, can cause Cushing's syndrome.

Treatment options include medical therapy with ketoconazole, mifepristone, aminoglutethimide, metyrapone, or mitotane.

View source ↗